CAMBRIDGE, Mass.--(BUSINESS WIRE)--Unum Therapeutics, a clinical stage biopharmaceutical company developing a universal cellular immunotherapy to treat multiple cancers, today announced that the Company has been selected for two poster presentations on its Antibody-Coupled T-cell Receptor (ACTR) platform at the 58th ASH Annual Meeting, which is being held in San Diego, California, December 3-6, 2016.
In addition, Dr. Michelle Poon of the NUH in Singapore, will be presenting initial results of an ongoing Investigator Sponsored Trial using autologous T-cells with ACTR transiently expressed through mRNA electroporation in combination with rituximab in patients with relapsed/refractory CD20+ B-cell Non Hodgkin lymphoma (B-NHL) (ATTCK20; ClinicalTrials.gov No. NCT02315118). Following the initial results of this ongoing trial, Unum recently announced the initiation of a clinical trial for patients with relapsed/refractory CD20+ B-NHL in which ACTR is durably expressed through viral delivery in autologous T-cells (ACTR087; ClinicalTrials.gov No. NCT02776813).
Presentation Details:
Presentation Title: Targeting CD20+ Relapsed Refractory B-Cell
Lymphoma with ACTR087, Antibody-Coupled T-Cell Receptor (ACTR)
Engineered Autologous T-Cells, in Combination with Rituximab
Presenter:
Heather A. Huet, Senior Director of Drug Discovery, Unum Therapeutics
Presentation
Date: Sunday, December 4, 2016
Presentation Time: 6:00
p.m.‐8:00 p.m.
Room: Hall GH (San Diego Convention Center)
Session: 801.
Gene Therapy and Transfer: Poster II
Abstract Number: 3512
Presentation Title: ACTR Platform as an Adaptable, Universal
T-Cell Therapy That Can Target Multiple Tumor Antigens to Overcome
Antigen Escape
Presenter: Greg Motz, Senior Scientist, Unum
Therapeutics
Presentation Date: Sunday, December 4, 2016
Presentation
Time: 6:00 p.m.‐8:00 p.m.
Room: Hall GH (San Diego
Convention Center)
Session: 703. Adoptive
Immunotherapy: Poster II
Abstract Number: 3362
Presentation Title: A First-in-Human Study of Autologous T
Lymphocytes with Antibody-Dependent Cell Cytotoxicity (ADCC) in Patients
with B-Cell Non-Hodgkin Lymphoma (NHL)
Presenter: Michelle
Poon, MD Senior Consultant, Department of Hematology-Oncology,
National
University Cancer Institute, Singapore (NCIS)
Presentation Date:
Sunday, December 4, 2016
Presentation Time: 6:00 p.m.‐8:00
p.m.
Room: Hall GH (San Diego Convention Center)
Session: 626.
Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell
Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster
II
Abstract Number: 3031
The posters will be posted on Unum’s website following the presentations.
About Antibody-Coupled T-Cell Receptor (ACTR) Technology and ACTR087
Unum’s
proprietary ACTR is a chimeric protein that combines components from
receptors normally found on two different human immune cell types –
natural killer (NK) cells and T-cells – to create a novel cancer cell
killing activity. T-cells bearing the ACTR receptor protein can be
directed to attack a tumor by combining with a monoclonal antibody that
binds antigens on the cancer cell surface.
In contrast to other T-cell therapy approaches for cancer that are limited to a single cancer cell surface target and, therefore, treat a narrow set of tumors, Unum’s approach is not restricted by a specific tumor cell antigen and, thus, may have applications for treating many different types of cancers when combined with the right antibody.
Unum is developing ACTR in combination with a range of tumor-targeting antibodies for use in both hematologic and solid tumor indications. ACTR087, Unum’s most advanced product candidate, combines Unum’s proprietary ACTR, with rituximab, an anti-CD20 antibody. The ACTR087 study will be the first clinical trial using a viral vector to permanently insert the ACTR gene into the genome of patient T-cells.
About Unum Therapeutics
Unum Therapeutics uses its
proprietary Antibody-Coupled T-cell Receptor (ACTR) technology in
combination with tumor-targeting antibodies, which is designed to
activate the body’s own immune system to fight cancer. Unum is actively
building a pipeline of ACTR programs in which proprietary,
tumor-targeting antibodies are armed to improve their therapeutic
potential. The Company is headquartered in Cambridge, MA. For more
information, visit www.unumrx.com/.